Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
TTS 2.45 −2.0% FCI 0.400 −9.1% GR 0.075 +0.0% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% S 0.155 +29.2% DEX 0.390 +1.3% TTS 2.45 −2.0% FCI 0.400 −9.1% GR 0.075 +0.0% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% S 0.155 +29.2% DEX 0.390 +1.3%
Other Routine +

The Precision Peptide Company Inc. Places Order for 20,000 BPC-157 Transdermal Patches

Precision Peptide Advances Commercial Launch with MMA Partnership Backing

By The Northwire Desk — AI Analysis May 26, 2026 · 07:31 BPC · 0.435 The Precision Peptide Company Inc.
Executive Summary
  • The company has placed an order for 20,000 units of its lead product candidate, a needle-free BPC-157 transdermal patch.
  • Initial commercial availability is targeted as early as June 2026 via the company website.
  • Independent testing by Miraxis Labs confirmed 95.5% chromatographic purity and a measured dose of 2.02 mg per patch.
  • This follows the strategic marketing agreement with MMA Inc., which provides access to over 5 million social media followers and 800+ verified gyms globally.
  • The partnership features a tiered revenue share: 50/50 in Year 1, transitioning to 75/25 in favor of Precision Peptide thereafter.
Material Impact
  • Validation of Roadmap: This news confirms the execution phase of the strategy announced on May 12, 2026 (MMA partnership) and validated by testing results on May 19, 2026. It moves the company from development to commercialization.
  • Revenue Catalyst: While positive, placing an order does not guarantee immediate sales revenue. The impact depends on sell-through velocity in June 2026.
  • Market Expectations: Given the explicit timeline set during the May 12 partnership announcement (commercial release anticipated), this news is largely expected by the market rather than a surprise upside event.
  • Risk Mitigation: Third-party testing results clear the industry benchmark, reducing regulatory and quality risk perception compared to unverified claims.
  • Rating Justification: Classified as Routine - Positive because it represents incremental progress on an already priced-in thesis (the MMA deal) without introducing new strategic investors or M&A activity that would constitute a Game Changer.
BPC · Price
Company Overview
  • Company: The Precision Peptide Company Inc. (CSE: BPC).
  • Flagship Project: BPC-157 transdermal patch. A needle-free delivery system designed to eliminate the need for injections, reconstitution, or sterile handling.
  • Pipeline: Includes an Immune Defense Patch (Thymosin Alpha-1) under development on the same platform.
  • Manufacturing: Products are manufactured in the United States and comply with FDA standards.
  • Distribution: Direct-to-consumer via website and strategic partnership with MMA Inc. for combat sports market access.
Read the original news release →

More from The Precision Peptide Company Inc.

Jun 23, 2026 · 07:31

Compliance milestones unlock e-commerce scaling, but regulatory clarity remains the true catalyst.

Other Jun 11, 2026 · 17:01

Pre-revenue peptide developer secures at-market capital to fund U.S. commercial rollout amid regulatory tailwinds.

Financings Jun 09, 2026 · 07:31

Building compliant U.S. telehealth and compounding infrastructure ahead of pivotal July FDA PCAC review.

M&A / Property Jun 02, 2026 · 07:01

The Precision Peptide Company Inc.

Financings May 21, 2026 · 09:00

McGregor and Trump Jr. muscle into peptide marketing pact, but needle-free patch launch remains the real prize

Financings May 21, 2026 · 07:31

Precision Peptide Solidifies MMA Partnership While Regulatory Clock Ticks Toward July Review

M&A / Property